CD6抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P07831(ALPK1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

CD6 is a cell surface glycoprotein predominantly expressed on T cells and a subset of B cells, first identified in the 1980s as a key marker for T-cell development and activation. Structurally, it belongs to the scavenger receptor cysteine-rich (SRCR) superfamily and interacts with its ligand CD166 (ALCAM), which is expressed on antigen-presenting cells (APCs) and epithelial cells. This interaction facilitates immunological synapse formation, enhancing T-cell activation, adhesion, and migration. CD6 has been implicated in modulating both pro-inflammatory and regulatory immune responses, making it a therapeutic target for autoimmune diseases and cancers.

Research on CD6-targeting antibodies gained momentum due to their potential to disrupt pathological T-cell activation while preserving immune surveillance. Early studies revealed that anti-CD6 antibodies could dampen T-cell proliferation and cytokine production in vitro, suggesting utility in conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis. Notably, Itolizumab, a humanized anti-CD6 monoclonal antibody, has shown efficacy in Phase III trials for chronic plaque psoriasis and has been explored in COVID-19-related cytokine storms. Its mechanism involves partial CD6 receptor modulation rather than complete blockade, reducing systemic immunosuppression risks.

Despite progress, challenges remain, including understanding CD6's dual roles in immune regulation and optimizing antibody specificity to minimize off-target effects. Ongoing studies aim to clarify its signaling pathways and expand clinical applications, positioning CD6 antibodies as promising biologics in immunotherapy.